827587-90-6

Basic information

• Product Name: 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine
• Synonyms: 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine;Morpholine, 4-[(6-amino-3-pyridinyl)carbonyl]-;5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine(WX609380);(6-AMINOPYRIDIN-3-YL)(MORPHOLINO)METHANONE
• CAS NO: 827587-90-6
• Molecular Formula: C₁₀H₁₃N₃O₂
• Molecular Weight: 207.22912
• Mol File: 827587-90-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine(827587-90-6)
• EPA Substance Registry System: 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine(827587-90-6)

Safety Data

• Hazardous Substances Data: 827587-90-6(Hazardous Substances Data)

Usage

General Description

5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine is a chemical compound with the molecular formula C12H13N3O2. It consists of a pyridine ring with an attached morpholine group and a carbonyl group. 5-[(Morpholin-4-Yl)Carbonyl]Pyridin-2-Amine is used in the pharmaceutical industry as a building block for the synthesis of various drugs and bioactive compounds. It has potential applications in the development of new medications for the treatment of various diseases and disorders. Additionally, it may have biological activities such as antimicrobial or anti-inflammatory properties, although further research is needed to fully understand its therapeutic potential.

Upstream product

• 110-91-8 morpholine 
• 3167-49-5 6-aminonicotinic acid 
• 39658-41-8 ethyl-6-amino-nicotinate 
• 231958-14-8 6-[(tert-butoxycarbonyl)amino]nicotinic acid 
• 144186-11-8 methyl 6-<(tert-butyloxycarbonyl)amino>nicotinoate 

Downstream Products

• 1147528-82-2 4-tert-butyl-N-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)pyridin-2-ylamino]-6-oxo-1,6-dihydropyridazin-3-yl}phenyl)benzamide 
• 1147529-48-3 7-tert-butyl-3-(2-methyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)pyridin-2-ylamino]-6-oxo-1,6-dihydropyridazin-3-yl}phenyl)-2,3-dihydro-1H-quinazolin-4-one 
• 1588421-89-9 1-ethyl-7-[5-(morpholine-4-carbonyl)pyridin-2-ylamino]-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1360056-36-5 2-[8-fluoro-2-(2-formyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-1-oxo-1,2-dihydro-isoquinolin-6-yl]-2-methyl-propionitrile 
• 1360055-16-8 2-[8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-1-oxo-1,2-dihydro-isoquinolin-6-yl]-2-methyl-propionitrile 
• 1360055-03-3 6-tert-Butyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridazin-3-yl}-phenyl)-2H-phthalazin-1-one 

Relevant articles and documents

HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are heteroaryl heterocyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein the variables are as defined in the description.

PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.